Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).

Abstract

Overexpression of B-cell leukemia/lymphoma 2 (BCL2) renders acute myeloid leukemia (AML) cells resistant to chemotherapy and has been associated with unfavorable outcomes. Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide directed against the first 6 BCL2 codons. In a phase 1 study of AML patients treated with G3139, cytarabine, and daunorubicin induction with cytarabine consolidation, no antisense-related toxicity was reported, and BCL2 downregulation occurred in patients achieving complete remission. In this phase 3 trial, untreated older AML patients were randomized to cytarabine (100 mg/m2 per day on days 4-10) and daunorubicin (60 mg/m2 per day on days 4-6) followed by cytarabine consolidation (2000 mg/m2 per day on days 4-8) with (arm A) or without (arm B) G3139 (7 mg/m2 per day on days 1-10 [induction] or days 1-8 [consolidation]). A total of 506 patients were enrolled. No differences in toxicity were observed between arms. Estimated overall survival (OS) at 1 year was 43% for arm A and 40% for arm B (1-sided log rank P = .13), with no differences in disease-free (DFS; P = .26) or event-free survival (P = .80). Subgroup analyses showed patients age <70 years in arm A had improved OS by 1 month vs those in arm B (P = .04), and patients with secondary AML in arm A had better DFS vs those in arm B (P = .04). We conclude that addition of G3139 to chemotherapy failed to improve outcomes of older AML patients. However, more effective means of inhibiting BCL2 are showing promising results in combination with chemotherapy in AML. This trial was registered at www.clinicaltrials.gov as #NCT00085124.

• Authors: Alison R Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J Carroll, Ann-Kathrin Eisfeld, Eunice S Wang, Sawyer Jacobson, Jonathan E Kolitz, Mohan Thakuri, Grerk Sutamtewagul, Ravi Vij, Robert K Stuart, John C Byrd, Clara D Bloomfield, Richard M Stone, Richard A Larson
• Journal: Blood advances (Blood Adv) Vol. 5 Issue 13 Pg. 2775-2787 (07 13 2021) ISSN: 2473-9537 [Electronic] United States
• PMID: 34251414 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
• Copyright: © 2021 by The American Society of Hematology.

Chemical References

• Thionucleotides
• Cytarabine
• oblimersen

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cytarabine (therapeutic use)
• Humans
• Leukemia, Myeloid, Acute (drug therapy)
• Thionucleotides (therapeutic use)